Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives

被引:4
|
作者
Ruiz-Villaverde, Ricardo [1 ]
Vasquez-Chinchay, Fiorella [2 ]
Rodriguez-Fernandez-Freire, Lourdes [3 ]
Armario-Hita, Jose C. [4 ]
Perez-Gil, Amalia [5 ]
Galan-Gutierrez, Manuel [6 ]
机构
[1] Hosp Univ San Cecilio, Dermatol Dept, Avda Conocimiento 33, Granada 18016, Spain
[2] Hosp Quiron Salud Sagrad Corazon, Dermatol Dept, Seville 41013, Spain
[3] Hosp Univ Virgen del Rocio, Dermatol Dept, Seville 41013, Spain
[4] Hosp Univ Puerto Real, Dermatol Dept, Cadiz 11510, Spain
[5] Hosp Univ Virgen de Valme, Dermatol Dept, Seville 41014, Spain
[6] Hosp Univ Reina Sofia, Dermatol Dept, Cordoba 14004, Spain
来源
LIFE-BASEL | 2022年 / 12卷 / 09期
关键词
guselkumab; psoriasis; super-responder; VOYAGE; 1; URTICARIA; PROGNOSIS;
D O I
10.3390/life12091412
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
A fast skin clearance is the main goal to achieve in psoriasis treatment. Patients that present a fast and exceptional improvement with treatment are called super-responders (SR). There is no consensus on the definition of SR with respect to psoriasis. Included herein is a retrospective analysis of a multicenter, observational study of real clinical practices including patients with moderate-to-severe plaque PSO undergoing treatment with Guselkumab (GUS). This cross-sectional analysis includes information on patients between February 2019 to February 2022. A SR is a patient that achieved a PASI = 0 at weeks 12 and 24. Analyses have been performed "as observed" using GraphPad Prism version 8.3.0 for Windows (GraphPad Software, San Diego, CA, USA, At baseline, the PASI is significantly correlated with VAS_pruritus, BSA, and DLQI, while DLQI is significantly correlated with VAS_pruritus. Significant correlations increase in number and magnitude over the follow-up time. In relation to the univariate logistic models carried out, only three variables showed a significant association with the super-responder variable: depression, VAS_pruritus, and DLQI.SR patients, who show a faster evolution in PASI and BSA improvement than non-SRs. Based on the results obtained, it would be possible to also include DLQI and VAS_pruritus in the broader concept of the SR.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series
    Ruiz-Villaverde, Ricardo
    Rodriguez-Fernandez-Freire, Lourdes
    Armario-Hita, Jose C.
    Perez-Gil, Amalia
    Galan-Gutierrez, Manuel
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (08) : 1029 - 1033
  • [2] Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials
    Reich, Kristian
    Strober, Bruce
    Langley, Richard
    Song, Michael
    Shen, Yaung-Kaung
    You, Yin
    Foley, Peter
    Blauvelt, Andrew
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB145 - AB145
  • [3] Characterization of super responders to guselkumab treatment in moderate-to-severe psoriasis: results from the VOYAGE 1 and 2 clinical trials
    Reich, K.
    Gordon, K. B.
    Strober, B.
    Langley, R. G.
    Song, M.
    Shen, Y-K
    You, Y.
    Foley, P.
    Blauvelt, A.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 55 - 56
  • [4] Efficacy of Ustekinumab in the Treatment of Moderate-Severe Psoriasis
    Jimenez-Puya, R.
    Moreno, J. C.
    [J]. ACTAS DERMO-SIFILIOGRAFICAS, 2012, 103 : 16 - 24
  • [5] Guselkumab for the treatment of adults with moderate to severe plaque psoriasis
    Puig, Lluis
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (06) : 589 - 597
  • [6] Guselkumab in the treatment of moderate-to-severe plaque psoriasis
    Lopez-Sanchez, Cristina
    Puig, Lluis
    [J]. IMMUNOTHERAPY, 2020, 12 (06) : 355 - 371
  • [7] Guselkumab for the treatment of moderate-to-severe plaque psoriasis
    Yang, Eric J.
    Sanchez, Isabelle M.
    Beck, Kristen
    Sekhon, Sahil
    Wu, Jashin J.
    Bhutani, Tina
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (04) : 333 - 344
  • [8] Super-responders in psoriasis under interleukin 23 inhibitor treatments, experience in two centres
    Sanchez, M. Menendez
    de Lucas, A. Muniz
    Fernandez, E. Perez
    Velasco, M. Llamas
    Genao, D. P. Ruiz
    Estebaranz, J. L. Lopez
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (11) : E1321 - E1322
  • [9] Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study
    Loft, N.
    Egeberg, A.
    Rasmussen, M. K.
    Bryld, L. E.
    Nissen, C., V
    Dam, T. N.
    Ajgeiy, K. K.
    Iversen, L.
    Skov, L.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (08) : 1284 - 1291
  • [10] Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
    Light, Jeremy G.
    Su, Jennifer J.
    Feldman, Steven R.
    [J]. CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2021, 14 : 55 - 63